[1] Lenders JWM, Duh Q, Eisenhofer G, et al.Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2014, 99(6): 1915-1942. [2] 中华医学会内分泌学分会肾上腺学组. 嗜铬细胞瘤和副神经节瘤诊断治疗的专家共识[J]. 中华内分泌代谢杂志,2016, 32(3):181-187. [3] Fishbein L, Leshchiner I, Walter V, et al.Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma[J]. Cancer Cell, 2017, 31(2): 181-193. [4] 罗智文, 李友伟, 谢辉. 腹腔镜手术治疗肝尾状叶异位嗜铬细胞瘤1例报告[J]. 腹腔镜外科杂志, 2022, 27(11):876-878. [5] 童安莉, 李汉忠. 多发内分泌肿瘤治疗共识与争议[J]. 协和医学杂志, 2020, 11(4):365-69. [6] Liao W, Ding Z, Zhang B, et al.Primary functioning hepatic paraganglioma mimicking hepatocellular carcinoma: A case report and literature review[J]. Medicine (Baltimore), 2018, 97(17): e0293. [7] 马晓森, 童安莉. 嗜铬细胞瘤分子病因学研究进展[J]. 国际内分泌代谢杂志, 2021, 41(2):82-86. [8] 李蓉, 孙浩然, 王红, 等. 嗜铬细胞瘤的典型及不典型CT和MRI特征[J]. 中国医学影像学杂志, 2019, 27(12):926-931. [9] Timmers HJLM, Taïeb D, Pacak K, et al.Imaging of Pheochromocytomas and Paragangliomas[J]. Endocr Rev, 2024, 45(3): 414-434. [10] Lenders JWM, Pacak K, Walther MM, et al.Biochemical diagnosis of pheochromocytoma: which test is best[J]. JAMA, 2002, 287(11): 1427-1434. [11] Eisenhofer G, Pamporaki C, Lenders JWM.Biochemical Assessment of Pheochromocytoma and Paraganglioma[J]. Endocr Rev, 2023, 44(5): 862-909. [12] Naruse M, Jr WFY.Targeted molecular medicine: advances in the treatment of metastatic phaeochromocytoma and paraganglioma[J]. Lancet, 2024, 403(10431): 1001-1003. [13] Santo GD, Santo G, Sviridenko A, et al.Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023[J]. Theranostics, 2024, 14(3): 940-953. [14] Hulsteijn LTV, Niemeijer ND, Dekkers OM, et al.(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis[J]. Clin Endocrinol (Oxf), 2014, 80(4): 487-501. |